期刊文献+

肺靶向顺铂隐形泡囊的研制及其体外生物学性质 被引量:2

Preparation of lung-targeting Cisplatin stealth niosomes and evaluation of their in vitro characteristics
下载PDF
导出
摘要 目的研制具有肺部靶向作用的隐形泡囊并进行体外抗癌细胞的实验评价。方法将亲水聚合物与胆固醇相连,考察含不同种类亲水链及含不同密度亲水链的隐形泡囊的包封率、稳定性和巨噬细胞吞噬作用,以最佳泡囊处方进行癌细胞生长抑制实验。结果用PluronicF68合成的胆固醇结合物所制隐形泡囊的包封率和固有水化层厚度较高,粒径合适;当胆固醇/Chol-PluronicF68的重量比为1:2.52时,泡囊的包封率、稳定性和体外规避巨噬细胞摄取等均较好,并具有和顺铂相似的抑制癌细胞生长的作用,粒径平均为8.432±0.043μm,有71.30%以上在被动肺靶向要求的7~25μm范围内,抑制癌细胞生长的结果与原料药顺铂相同。结论隐形泡囊制备简单,具有一定的隐形效果,能保持原药的抗癌活性,粒径范围符合被动肺靶向的要求。 OBJECTIVE To prepare lung - targeting Cisplatin stealth niosomes and evaluate their antitumor efficiency in vitro. METHODS Several hydrophilic polymers were conjugated with cholesterol. Stealth niosomes with different kinds of hydrophilic poly- mers and with different density of hydrophilic chains were investigated in terms of entrapment efficiency, stability and phagocytosis test to choose the best formulation for antitumor experiments. RESULTS Stealth niosomes containing Pluronic F68 were chosen based on encapsulation efficiency, fixed aqueous layer thickness and suitable particle size. Stealth niosomes with a weight ratio of 1 : 2.52 of cholesterol/high cholerterol - PluronicF68 were chosen for the subsequent experiments because of their high entrapment efficiency, sta- bility and low uptaken percentage in vitro. The mean size of particles was 8. 432 ± 0. 043 μm with 71.30% of the total hiosomes in the range of 7 - 25μm, which met the requirement of lung - targeting. Antitumor efficiency of the stealth niosomes was similar to Cisplatin solution. CONCLUSION The preparation method of stealth niosomes was simple and convenient. The stealth niosomes could maintain the antitumor activity of the drug and evade phagocytosis. The particle size range can meet the challenge of lung - targeting.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第1期1-5,共5页 West China Journal of Pharmaceutical Sciences
基金 国家自然科学基金资助项目(批准号:30572262)
关键词 肺靶向 隐形泡囊 顺铂 吞噬 抗癌活性 Lung - targeting Stealth niosome Cisplatin Phagocytosis Antitumor activity
  • 相关文献

参考文献11

  • 1李清钊,刘桂香,姚林.顺铂对机体损伤及茶多酚的拮抗作用[J].华西药学杂志,2001,16(1):36-37. 被引量:5
  • 2Gryparis EC, Hatziapostolou M, Papadimitriou E, et al. Anticancer activity of cisplatin - loaded PLGA - mPEG nanoparticles on LNCaP prostate cancer ceils [ J ]. Euro J Pharm & Biopharm, 2007,67 : 1 - 8.
  • 3Huo DJ, Deng SH, Li LB, et al. Studies on the poly(lactic -co - glycolie) aeid mierospheres of eisplatin for lung - targeting [ J]. Int J Pharm, 2005,289:63 - 67.
  • 4Bontha S, Kabanov AV, Bronich TK. Polymer micelles with cross - linked ionic cores for delivery of anticancer drugs [ J ]. J Controlled Release, 2006,114 : 163 - 174.
  • 5Lu B, Zhang JQ, Yang H. Lung - targeting microspheres of carboplatin [J]. Int J Pharm, 2003, 265(1 -2) :1 -11.
  • 6张明,侯世祥,龚涛,程宇慧,廖工铁.肺靶向顺铂白蛋白微球含量的衍生化测定法[J].中国药学杂志,1994,29(6):355-357. 被引量:4
  • 7张志贤,张瑞镐.有机官能团定性分析[M].北京:化学工业出版社,1990.185-201.
  • 8Harris JM, Evelyn CS, Martha GC, et al. Synthesis and characterization of poly ( ethylene glycol) derivatives [ J ]. J Polymer Science, 1984, 22:341 -352.
  • 9陈永,杨红,陆彬,李玫,宗太丽.肺靶向顺铂泡囊的研制与体外性质的评价[J].华西药学杂志,2008,23(2):129-132. 被引量:8
  • 10Sadzuka Y, Nakade A, Tsuruda T, et al. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin [J]. J Control Release, 2003, 91(3) : 271 -280.

二级参考文献21

  • 1李革新,姚书杰,陆春伟,金亚平,孙贵范.顺铂肾毒性的实验研究[J].中国工业医学杂志,2004,17(3):186-187. 被引量:9
  • 2张明,侯世祥,龚涛,程宇慧,廖工铁.肺靶向顺铂白蛋白微球含量的衍生化测定法[J].中国药学杂志,1994,29(6):355-357. 被引量:4
  • 3王民生,海德堡.碱性单细胞微量凝胶电泳测试技术简介[J].癌变.畸变.突变,1996,8(2):112-115. 被引量:41
  • 4许向阳,周建平,李玲,卢是玥,杨洁.N-正辛基-N′-琥珀酰基壳聚糖的制备及其对4种肿瘤细胞的亲和性[J].中国新药与临床杂志,2007,26(5):355-359. 被引量:11
  • 5GREISH K, SAWA T, FANG J, et al. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours [ J ]. J Controlled Release ,2004,97 (2) :219-230.
  • 6NGIMHUANG J, FURUKAWA J I, SATOH T, et al. Synthesis of a novel polymeric surfactant by reductive N-alkylation of chitosan with 3-O-dodecyl-d-glucose [ J ]. Polymer, 2004, 45 ( 3 ) : 837-841.
  • 7SON Y J, JANG J S, CHO Y W, et al. Biodistribution and antitumor efficacy of doxorubiein loaded glycol-ehitosan nanoaggregates by EPR effect[J]. J Controlled Release, 2003, 91 ( 1- 2) :135-145.
  • 8MITRA S, GAUR P C, GHOSH P C, et al. Tumour targeted delivery of encapsulated dextran doxorubicin conjugate using chitosan nanoparticles as carrier[J]. J CuntruUed Release, 2001, 74 (1-3) :317-323.
  • 9PARK J H, CHO Y W, CHUNG H, et al. Synthesis and characterization of sugar-bearing chitosan derivatives : aqueous solubility and biodegradability [J] . Biomacromolecules, 2003, 4 ( 4 ) : 1087-1091.
  • 10KHOR E, LIM L Y. lmplantable applications of chitin and chitosan [J]. Biomaterials, 2003, 24 ( 13 ) :2339-2349.

共引文献19

同被引文献23

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部